PGNY vs. SHC, AGL, DVA, BHC, XENE, CRNX, FOLD, HCM, ENOV, and SGRY
Should you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Sotera Health (SHC), agilon health (AGL), DaVita (DVA), Bausch Health Companies (BHC), Xenon Pharmaceuticals (XENE), Crinetics Pharmaceuticals (CRNX), Amicus Therapeutics (FOLD), HUTCHMED (HCM), Enovis (ENOV), and Surgery Partners (SGRY). These companies are all part of the "medical" sector.
Sotera Health (NASDAQ:SHC) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
In the previous week, Progyny had 3 more articles in the media than Sotera Health. MarketBeat recorded 4 mentions for Progyny and 1 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.84 beat Progyny's score of 0.00 indicating that Progyny is being referred to more favorably in the news media.
Progyny has a net margin of 5.70% compared to Progyny's net margin of 4.90%. Progyny's return on equity of 51.32% beat Sotera Health's return on equity.
Progyny has higher revenue and earnings than Sotera Health. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
91.0% of Sotera Health shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 55.1% of Sotera Health shares are held by insiders. Comparatively, 12.3% of Progyny shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Progyny received 37 more outperform votes than Sotera Health when rated by MarketBeat users. Likewise, 74.55% of users gave Progyny an outperform vote while only 56.96% of users gave Sotera Health an outperform vote.
Sotera Health currently has a consensus price target of $17.70, suggesting a potential upside of 57.05%. Progyny has a consensus price target of $48.30, suggesting a potential upside of 48.16%. Given Progyny's higher probable upside, research analysts plainly believe Sotera Health is more favorable than Progyny.
Sotera Health has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.
Summary
Progyny beats Sotera Health on 12 of the 18 factors compared between the two stocks.
Get Progyny News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
